SCHEDULE 13G/A: Janus Henderson Group Discloses 5.5% Stake in Revolution Medicines, Inc.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing its beneficial ownership of 5.5% of Revolution Medicines, Inc.'s common stock as of March 31, 2025.

Summary

• Janus Henderson Group plc, a Jersey-based investment firm, has filed an Amendment No. 1 to its Schedule 13G regarding Revolution Medicines, Inc.
• The filing indicates that Janus Henderson Group plc beneficially owns an aggregate of 10,209,927 shares of Revolution Medicines, Inc. Common Stock.
• This ownership represents 5.5% of the total outstanding shares of Revolution Medicines, Inc.
• The shares are held with shared voting power and shared dispositive power.
• The filing date for the event requiring this statement was March 31, 2025.

Sentiment

Score: 5

Explanation: The document is a factual, compliance-driven disclosure of beneficial ownership and does not contain information that would inherently convey positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• The disclosure of a significant institutional holding by Janus Henderson Group plc may signal institutional confidence in Revolution Medicines, Inc.

Negatives

• Not applicable as this document is a Schedule 13G filing, which primarily discloses beneficial ownership and does not contain negative operational or financial performance data.

Risks

• Not applicable as this document is a Schedule 13G filing, which primarily discloses beneficial ownership and does not detail company-specific risks or future challenges.

Future Outlook

Not applicable as this document is a Schedule 13G filing, which primarily discloses beneficial ownership and does not provide forward-looking statements or guidance from the issuer.

Management Comments

• Janus Henderson Group plc certifies that, to the best of its knowledge and belief, the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Industry Context

This Schedule 13G filing indicates that a major investment management firm, Janus Henderson Group plc, holds a significant passive stake in Revolution Medicines, Inc. Such filings are routine disclosures by institutional investors when their beneficial ownership in a public company exceeds 5%, signaling their position in the market without intending to influence control.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding by Janus Henderson Group plc may be viewed as a vote of confidence, potentially influencing investor sentiment positively.
• Management: Awareness of a large institutional holder may influence management's strategic considerations, though the filing explicitly states no intent to influence control.

Next Steps

• Janus Henderson Group plc will file further amendments to this Schedule 13G if there are material changes to its beneficial ownership of Revolution Medicines, Inc. shares.

Key Dates

Keywords

SEC filing, Schedule 13G, beneficial ownership, Revolution Medicines, Janus Henderson Group, common stock, institutional investment, investment adviser, biotechnology, pharmaceuticals